WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of AMGEN (AMGN)

Name AMGEN
Year low 47.66
Year High 72.00
Symbol AMGN
Last trade 69.15
Percentage change -1.97
Volume 5,800,429
Media Volume (3m) 4,735,800
PE Ratio 16.54
EPS 4.265
Market Cap 53778
Media fatt 15953
Trend fatt trend fatt graph for AMGEN
Media net income 3429
Trend net income trend net income for AMGEN
P / E P / E graph for AMGEN - 13 points 13
EPS EPS graph for AMGEN - 15 points 15
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for AMGEN - 2 points 2
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for AMGEN - 6 points 6
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for AMGEN - 11 points 11
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for AMGEN - 13 points 13
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for AMGEN - 3 points 3
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for AMGEN - 4 points 4
NET INC1/NET INC3 net inc1/net inc3 graph for AMGEN - 10 points 10
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for AMGEN - 4 points 4
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for AMGEN - 10 points 10
. . graph for AMGEN - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for AMGEN - 2 points 2
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for AMGEN - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for AMGEN - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for AMGEN - 1 points 1
. . graph for AMGEN - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for AMGEN - 0 points 0
SINTESE 94

GRAPHS

max price logarithm graph for AMGEN based on no conditions max volume linear graph for AMGEN based on no conditions

News

/C O R R E C T I O N -- Amgen/ (May 19 - reuters) Critical Success Factors For The Immunotherapy Race (May 17 - reuters) Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer (May 17 - reuters) Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (May 17 - reuters) Top 5 Biotech ETFs (May 15 - reuters) Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars (May 11 - reuters) Checking Amgen's Intangibles (May 09 - reuters) This Biopharmaceutical Could Be Something Special (May 08 - reuters) 4.4%+ High Yield Ex-Dividend Opportunities (May 07 - reuters) Amgen to Present at the Baird Growth Stock Conference (May 04 - reuters) Amgen to Present at the Deutsche Bank 37th Annual Healthcare Conference (May 04 - reuters) 3 Overvalued Pharmaceutical Stocks That May Tumble By 2013 (May 03 - reuters) 5 Healthy Dividend Growth Stocks To Cure What Ails Your Portfolio (May 03 - reuters) Pfizer Looks Fine Post-Tornado (May 03 - reuters) Finding An Oncology Player That Will Change The Rules Of The Game (May 02 - reuters) Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California (May 02 - reuters) UPDATE 1-FDA rejects Amgen's application for Xgeva (Apr 27 - reuters) FDA rejects Amgen's application for Xgeva (Apr 27 - reuters) Amgen Receives Complete Response Letter From FDA for XGEVA® sBLA for Prevention of Bone Metastases (Apr 27 - reuters) Amgen Looking, Thinking, And Acting More Like A Pharma Co. (Apr 26 - reuters) Vivus Could Skyrocket On Avanafil, Qnexa Approval (Apr 25 - reuters) Vertex Is Ready To Rise On INCIVEK Success (Apr 25 - reuters) Amgen to buy Turkish drugmaker for $700 million (Apr 25 - reuters) Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company (Apr 25 - reuters) Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript (Apr 25 - reuters) Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61 (Apr 24 - reuters) Amgen quarterly net profit rises 5 percent (Apr 24 - reuters) Earnings Preview: Amgen (Apr 24 - reuters) Best And Worst ETFs And Mutual Funds: Health Care (Apr 24 - reuters) Analysis: New Amgen CEO must win investors with payouts, deals (Apr 24 - reuters) Amgen founding CEO George Rathmann dies at 84 (Apr 24 - reuters) A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012) (Apr 24 - reuters) Amgen Announces Webcast of 2012 First Quarter Financial Results (Apr 19 - reuters) Amgen: Earnings Preview (Apr 19 - reuters) Large-Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers (Apr 17 - reuters) AstraZeneca Needs the Right Formula (Apr 11 - reuters) ArQule Dips, But Not Necessarily A Bargain (Apr 10 - reuters) Breaking The Mold Of Oncology Drug Development (Apr 10 - reuters) Amgen to Acquire Privately Held KAI Pharmaceuticals (Apr 10 - reuters) Keryx: Next Shot Is Zerenex (Apr 09 - reuters) Amgen And AstraZeneca To Collaborate On Inflammation Portfolio (Apr 09 - reuters) Time To Take Another Look At The Biotechnology Sector (Apr 09 - reuters) iBio Incorporated: Speculative Long Term Investment With Short Term Catalyst (Apr 09 - reuters) UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis (Apr 04 - reuters) AstraZeneca hunting more deals like Amgen tie-up (Apr 03 - reuters) Affymax Poised To Take On Amgen? (Apr 03 - reuters) Amgen, Astra to collaborate on several drugs (Apr 03 - reuters) Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio (Apr 03 - reuters) Amgen, Astra to collaborate on several drugs (Apr 03 - reuters) Affymax's Anemia Drug Will Create Added Competition For Amgen (Apr 01 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY